Telik Announces FDA Orphan Designation Of Telintra for Treatment Of Myelodysplastic Syndrome
Posted on January 11, 2013 at 19:53 PM EST
Telik (NASDAQ: TELK ) was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS). Orphan designation grants potential US market exclusivity to a drug for the treatment of